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Abstract 
Introduction. The characteristics of Group B Streptococcal (GBS) early onset (EOD) 
and late onset (LOD) neonatal infections in Italy were analyzed. Two periods were 
considered, a first 3-years period (2007-2010), when notification of GBS infections was 
enforced under the auspices of the Italian Ministry of Health, and a  second 1 year period 
(2012) when reporting on neonatal GBS disease continued on voluntary basis.
Methods. A standardized form was used to collect data on cases of neonatal GBS 
disease. They included both maternal and neonatal data. 
Results and discussion. The two surveys underlined that preterm deliveries, precipitous 
labor and negatively GBS screened mothers are common causes of EOD occurrence, 
possibly explained by inadequate, or lack of, intrapartum antibiotic prophylaxis. 
Nevertheless, measures for reducing prevention failures and EOD incidence by an higher 
adherence to prevention strategies, as the Centre for Disease Control recommendations, 
are still possible and should be encouraged. 
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Streptococcus agalactiae (Group B Streptococcus, GBS) 
is a commensal of the human intestinal and genito-uri-
nary tract. As a pathogen, GBS emerged in the 1970s 
as the leading cause of invasive perinatal infections in 
developed countries [1].
Invasive GBS infections can present either with an 
early onset disease (EOD) that occurs generally with-
in 12 hours as respiratory distress, apnea, leading to 
sepsis and/or pneumonia or with a late onset disease 
(LOD) occurring between one week and three months 
of life and accounting for most meningitis cases and 
deaths [2, 3].
Up to 30% of pregnant women can be asymptomati-
cally colonized with GBS in the vagina and/or rectum 
and represent the primary risk factor for the vertical 
transmission during labor. In the absence of any pre-
vention strategies, about 50% of neonates born to GBS 
colonized mothers are colonized at the mucosal and 
skin sites and an estimated 1-2% develop early-onset 
GBS invasive infections [4, 5]. 
Prevention strategies consider an intrapartum antibi-
otic prophylaxis (IAP) by the intravenous administra-
tion of penicillin/ampicillin (or clindamycin in the case 
of serious penicillin allergy) to parturient women in all 
cases that increase the risk for EOD. Guidelines rec-
ommend the use of one of two approaches to identify-
ing women who should receive intrapartum antibiotic 
prophylaxis: a risk-based approach or a culture-based 
screening approach. The risk-based method identifies 
candidates for intrapartum chemoprophylaxis accord-
ing to the presence of any of the following intrapartum 
risk factors: delivery at < 37 weeks’ gestation, intrapar-
tum temperature ≥ 38.0 ºC or rupture of membranes 
for ≥ 18 hours. The culture-based screening method 
consists in the screening of all pregnant women for 
vaginal and rectal GBS colonization between 35 and 37 
week’s gestation. Colonized women are offered intra-
partum antibiotics at the time of labor onset or rupture 
of membranes if before labor [6-8]. 
In US, EOD has declined by 70% since increased use 
of intrapartum antibiotic prophylaxis has occurred in 
the early 1990s; nevertheless, this approach has had only 
a slight effect in the reduction of LOD. Since 2002, the 
US Centre for Diseases Control (CDC) recommenda-
tions for the prevention of the newborn invasive GBS 
disease opted for the universal prenatal culture-based 
screening approach [9].
























In Europe, routine bacteriological screening of all 
pregnant women for antenatal GBS carriage to opti-
mize the identification of women who should receive 
IAP is recommended as part of national guidelines in 
Spain (1998), France (2001), Belgium (2003), Ger-
many (1996), Czech Republic (2008), Poland (2008), 
Switzerland (2007) but not in UK, Holland and Nor-
way that opted for the risk-based approach [10-13].
Under both strategies, intrapartum antibiotic proph-
ylaxis is recommended for women with GBS bacteriu-
ria at any time during their current pregnancy or for 
women who had given birth previously to an infant with 
invasive early onset GBS disease. Intrapartum antibi-
otic prophylaxis is not indicated, if a cesarean delivery is 
performed before onset of labor on a woman with intact 
amniotic membranes, regardless of GBS colonization 
status or gestational age [9].
In Italy neither guidelines for the prevention of group 
B Streptococcus invasive neonatal infections nor an ac-
tive surveillance system for the notification of disease 
exist. In November 2010 the recommendation for GBS 
antenatal screening (vaginal-rectal swab at 36-37 weeks 
of gestation) and IAP for carriers has been included in 
a guideline promoted by the Italian Ministry of Health 
regarding routine controls schedule in pregnancy [14]. 
The test is on payment because, despite the recommen-
dation, it is not included in the list of the national health 
services freely provided to pregnant women [15-18].
Only an Italian Region, Emilia-Romagna (ER), locat-
ed in the northern part of Italy, has set up a local GBS 
Working Group since 2003, promoting common pre-
vention strategies according to the CDC recommenda-
tions for an universal screening-based approach. This 
group has produced valuable data on the incidence of 
GBS disease and clinical features of early and late onset 
GBS disease in ER [19-25]. 
A multicentre study, funded by the Italian Ministry of 
Health and coordinated by the Italian National Insti-
tute of Health (Istituto Superiore di Sanità, ISS) on the 
invasive neonatal GBS infections was pursued in the 
years 2007-2010 [17]. After that, the reporting on neo-
natal GBS disease to ISS continues on voluntary basis.
This paper compares the clinical characteristics of ne-
onatal GBS cases collected both during the multicentre 
study and the year 2012.
METHODS
A standardized form, inspired to that adopted in 
ER, was used to collect data on cases of neonatal GBS 
disease. They included both maternal data (antenatal 
colonization, gestational age, ethnicity, mode of deliv-
ery, risk factors, antibiotic administration) and neonatal 
data (sex, ethnicity, onset of symptoms, clinical mani-
festation, outcome, hospital stay duration, site of GBS 
isolation). The operational protocol adopted during the 
2007-2010 multicentre study identified as GBS neo-
natal infections only culture proven cases where GBS 
was isolated from a normally sterile body site such as 
blood or cerebrospinal fluid (CSF) in infants aged ≤ 90 
days, while also cases of clinical sepsis (where GBS was 
isolated from broncoalveolar lavage or gastric aspirate) 
were accepted during the surveillance in the year 2012.
The GBS Working Group of Emilia-Romagna and 
nine hospitals located in different part of Italy, covering 
about one tenth of national annual births, participated 
to the 2007-2010 multicentre study while the year 2012 
surveillance relied on the notification by any national 
hospital on voluntary basis.
In both surveillance periods, all participating birth 
centres reported to follow CDC recommendations.
RESULTS AND DISCUSSION
In the years 2007-2010 a total of 89 cases were re-
ceived, of which 75.3% from the ER. In the year 2012, 
a total of 50 GBS neonatal infection notifications were 
received; in particular, 19 cases were from the GBS 
Working Group of Emilia-Romagna (38%) and the re-
maining cases from fourteen hospitals located in nine 
Italian Regions. These represent encouraging data, 
reflecting both the lowering of the incidence of GBS 
perinatal disease in ER due to the constant improve-
ment in the adherence to the prevention protocols (in 
2012, the incidence of the perinatal GBS disease was 
0.17 cases/1000 live births) and the higher participa-
tion and collaboration in the GBS cases notification by 
other national birth centres.
Table 1 summarizes the data collected on GBS neona-
tal infections in the years 2007-2010 compared to those 
collected in the year 2012. An interesting aspect in both 
the surveillance periods was the high proportion of in-
fections among preterm infants (27% in the first period 
and 22.5% in the second period). This finding could be 
explained by different considerations: often IAP pre-
venting the transmission of the infection by mother to 
neonate in the case of maternal GBS colonization could 
not be efficiently administrated in the case of precipi-
tous labor characterizing most of preterm deliveries; on 
the other side, the improved clinical management of 
very prematures neonates reduced the incidence of sep-
tic abortion cases. The percentage of mothers of these 
babies that received antenatal screening for GBS (72% 
and 80% in the two surveillances, respectively, Table 1) 
was lower than those of full-term babies (usually 90-
to-95%), because deliveries mostly occurred before the 
recommended gestational age for the antenatal screen-
ing [17, 24]. 
The most frequent clinical manifestation of neonatal 
GBS infection was sepsis, followed by bacteremia and 
meningitis. About 2% of mortality was registered in 
both surveillances. The hospital stay duration (surveyed 
only in the year 2012) was significantly higher in the 
case of preterm patients than in term infants affected 
by EOD, while no difference in the hospital stay length 
between pre-term and full-term patients was observed 
in the case of LOD (16-20 days).
About 35-40% of EOD were from negative screened 
mothers in both surveillance periods (Table 1 and Table 
2). This finding has been elsewhere reported [17, 22, 
24, 26, 27] and it constitutes, nowadays, the promi-
nent failure in the prevention strategies. As pointed 
out above, approximately 10%-30% of pregnant women 
are colonized with GBS in the vagina or rectum. The 
gastrointestinal tract serves as the primary reservoir for 
GBS and is the likely source of vaginal colonization. 

























Early onset disease (0-7 days) 45 cases 29 cases
Late onset disease (8-90 days) 44 cases 21 cases
Female/male ratio 1.12 0.75
Ethnical group
White European 89.4% 84.0%
Black African 11.2% 4.0%
Asian  3.4% 8.0%
Mixed  -- 2.0%
Not reported 10.1%
Prematurity (< 37 wks) 27% 22.5%
Bacterial isolation
Blood 78.6% 64.0%
Cerebrospinal fluid  6.8% 4.0%
Blood plus cerebrospinal fluid 10.1% 18.0%
Molecular identification test  4.5% --





Sepsis plus meningitis  4.5% 20.0% 
Septic shock  4.5% --
Septic arthritis  2.3% --
Cellulitis  1.1% --
Not reported 13.5% --
Clinical sepsis -- 14.0%
Outcome
Total recovery 62.9% 82.0%
Altered neuroimages  2.2% --
Permanent neurological sequelae  7.8% 8.0%
Mortality  2.2% 2.0%
Not reported 24.7% 8.0%
Hospital stay (average of days)
Early onset disease (preterm) -- 145 days
Early onset disease (term) -- 20 days
Late onset disease (preterm) -- 20 days
Late onset disease (term) -- 16 days
Maternal antenatal GBS screening 72.0% 80%
Positive 31.5% 32%
Negative 40.4% 48%
Negative mothers in early onset 
disease
42.2% 34.5%




Data collected on Group B Streptococcal (GBS) neonatal infec-
tions during the surveillance periods
Because GBS colonization status can change over the 
course of a pregnancy, the timing of specimen collec-
tion as well as the laboratory method used for specimen 
processing are very important. GBS cultures performed 
until less than 5 weeks before delivery are considered 
reliable [9]; nevertheless, the positive predictive value 
of prenatal cultures for GBS carriage during labor var-
ies through the literature and may sometime be lower 
[28, 29].
Regardless of the microbiological test selected to 
identify GBS, the use of a selective enrichment broth 
improves detection substantially. When direct agar plat-
ing is used instead of selective enrichment broth, only 
heavy colonization is detected and as many as 50% of 
women who are GBS carriers have false-negative cul-
ture results [9, 30]. 
The recommended combined rectal-vaginal swab-
bing increased sensitivity, but the relevant proportion 
of perinatal infections from negative mothers strongly 
suggests the real adherence to the specimen processing 
protocol should be evaluated and new solutions should 
be proposed. Rapid molecular diagnostic assays to be 
used at the time of delivery are being developed and 
could contribute to identify carrier women at labor to 
administrate IAP in a more proper way [9, 28]. 
In the case of LOD, up to 50% of mothers resulted 
negative to the antenatal screening, confirming an 
horizontal transmission as the cause of GBS infection 
and the relatively inefficiency of IAP in LOD preven-
tion (Table 2).
Table 2 reports the prevention strategies adopted at 
labor during the two surveillance periods, depending 
on the evaluation of maternal colonization status and 
presence of risk factors, only for those cases that sub-
sequently developed perinatal GBS infections. In case 
of antenatal positive screening, only 60% and 27.3% of 
women whose babies developed EOD received IAP in 
the two surveillance periods, respectively. In all cases 
but one the IAP was administered for less of the 4 
hours recommendation [9]. Precipitous delivery, often 
because of prematurity, was the main reason for an in-
adequate IAP. These observation is supported by other 
investigations where for as many as 45-50% of women 
is not possible to meet the 4 hours recommendation 
because of the rapidity of their labors [29; 31-34].
Other less frequent missed opportunities for preven-
tion included an inadequate route of antibiotic admin-
istration, the use of macrolides to which the GBS re-
sulted resistant, home delivery [17, 24].
When the antenatal screening was not performed and 
the evaluation of risk factors only at labor was done, 
the EOD cases were either from eligible mothers who 
didn’t receive IAP or received inadequate IAP (45.4% 
and 71.4%). 
Deviations to the CDC guidelines adherence was 
noted in the case of antenatal negative screening. Re-
gardless of intrapartum risk factors, CDC guidelines do 
not recommend IAP if parturients are not GBS colo-
nized. This approach is not always followed by national 
birth centres, most of which prefer to administrate IAP 
in this situation [17]. Also in this case, however, IAP 
failure and development of EOD occurred in 26.3% 
























and 27.2% respectively. The higher proportion of IAP 
failure because of the inadequate time of administra-
tion (deliveries with fewer than 4 hours of antibiotics) 
in the case of positive antenatal screening respect to 
when the antenatal screening was negative or not done, 
underlines that, among all risk factors responsible for 
the vertical bacterial transmission, the heavy maternal 
colonization remains the prominent cause for develop-
ing EOD [35].
In case of LOD, the relevant proportion of mothers 
who had received IAP (77% and 100% in the two sur-
veillance periods, respectively) confirmed its inefficacy 
in disease prevention and the importance of a better 
understanding of the bacterial transmission mode re-
sponsible for the onset of this perinatal infection. This 
observation is also confirmed by the microbiological 
characteristics of GBS bacterial strains responsible 
for EOD and LOD. The serotype distribution of GBS 
strains isolated both from EOD and vagino-rectal ante-
natal screening is very similar, confirming that the verti-
cal transmission from mother to baby is the principle 
cause of disease; on the other hand, more than 87% of 
LOD cases is caused by a particular clone, worldwide 
diffused [17, 36]. 
CONCLUSIONS
Preterm deliveries, precipitous labor and negative 
screened mothers are the prominent causes for an in-
adequate or lack of IAP and EOD occurrence. Never-
theless, measures for reducing prevention failures and 
EOD incidence by an higher adherence to the CDC 
recommendations are still possible and encouraged. 
A vaccine, currently under study [37, 38], to prevent 
group B Streptococcal disease could contribute to pre-
vent both EOD and LOD, the route of bacterial trans-
mission of the latter being poorly understood and for 
which CDC recommendations are ineffective. 
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2007-2010 Early onset disease 15 19 11
Risk factors 9 9 6
IAP > 4 hrs 0 0 0
IAP < 4hrs 9* 5 3**
CDC guidelines adherence 60% NA§ 45.4%
Late onset disease 13 17 14
Risk factors 2 5 9
IAP > 4 hrs 0 0 1
IAP < 4 hrs 10 4 3
CDC guidelines adherence 77% NA§ 28.6%
2012 Early onset disease 11 11 7
Risk factors 6 3 3
IAP > 4 hrs 1 1 0
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Risk factors 2 0 3
IAP > 4 hrs 1 0 1
IAP < 4 hrs 4 0 1
CDC guidelines adherence 100% 100% 66.6%
* In one case the route of administration was inadequate (oral) and in one case a not suitable antibiotic was administrated; ** in two cases the 
route of administration was inadequate (oral); § not applicable, because IAP was administered despite CDC recommendations.
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